Asymchem Clinical (Clin-nov) and Shandong Provincial Qianfoshan Hospital Form Catalytic Strategic Partnership
Asymchem Clinical (Clin-Nov)
Asymchem Clinical (Clin-nov) and Shandong Provincial Qianfoshan Hospital Form Strategic Partnership to Advance Clinical Research Jinan, China – August 28, 2024 –Asymchem Clinical (Clin-nov), a wholly-owned subsidiary of Asymchem Laboratories, announced today that it has signed a strategic cooperation agreement with the First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital). The partnership aims to strengthen collaboration in drug clinical trials, accelerate pharmaceutical innovation, and improve patient access to advanced therapies.
At the signing ceremony, Mr. Li Guangze, Deputy General Manager of Asymchem Clinical, and Ms. Li Junxia, Party Committee Member and Chief Accountant of Shandong Provincial Qianfoshan Hospital, represented both sides in formalizing the agreement. Senior leaders from both organizations, including Mr. Zhang Tieqiang, Senior Director of Procurement at Asymchem Clinical, and Dr. Xu Cuiping, Vice President of Shandong Provincial Qianfoshan Hospital and Director of its Drug Clinical Trial Institution, were also in attendance.
Dr. Xu welcomed the delegation and highlighted the hospital’s strengths in drug clinical research, emphasizing its commitment to supporting clinical trial quality and patient enrollment. She noted that the partnership would contribute to the hospital’s long-term strategy of advancing high-quality clinical research.
Mr. Li Guangze provided an overview of Asymchem Clinical’s development, strategic vision, and comprehensive service capabilities, underscoring the company’s dedication to building a robust partnership with the hospital.
Through this collaboration, the two organizations will:
● Leverage complementary strengths to expand clinical trial capacity.
● Enhance quality and efficiency through rigorous scientific and operational standards.
● Accelerate innovation in drug development to better serve patients in China and globally.
This partnership marks an important milestone in both parties’ efforts to integrate resources, foster innovation, and contribute to the advancement of China’s biopharmaceutical industry and public health initiatives.
About Shandong Provincial Qianfoshan Hospital
Founded in 1960, Shandong Provincial Qianfoshan Hospital is a leading tertiary medical institution recognized for its clinical excellence and research capabilities. Since becoming the First Affiliated Hospital of Shandong First Medical University in 2019, it has developed into a major training and research hub, supporting national programs in cardiology, surgery, neurology, respiratory medicine, and transplantation. The hospital is committed to building a world-class research-oriented institution that contributes to “Healthy Shandong” and “Healthy China.”
About Asymchem Clinical
Asymchem Clinical is a wholly-owned subsidiary of Asymchem Laboratories (SZSE: 002821; HKEX: 6821), a leading global CDMO. The company provides global, full-service, high-quality Regulatory and Clinical Development services worldwide, covering the entire spectrum from IND to NDA. Its integrated solutions include Pre-IND consulting, regulatory affairs, clinical monitoring, project management, SMO (site resources) services, data management and statistical programming, third-party auditing, pharmacovigilance, and post-marketing studies. Asymchem Clinical is dedicated to accelerating drug innovation and supporting partners in delivering breakthrough therapies to patients.
